Citations

Clear

32 citation(s) found for "Martin, David".

Pericardial late gadolinium enhancement and time to recurrence: a substudy from RHAPSODY, a phase 3 clinical trial of rilonacept in recurrent pericarditis
Lin, David , Abbate, Antonio , Jellis, Christine , Kwon, Debbie, Brucato, Antonio, Fang, Fang , LeWinter, Martin M. , Zou, Liangxing, Paolini, John F. , Investigators, RHAPSODY, Abo‐Auda, Wael, Akhtar, Asif, Arad, Michael , Baibhav, Bipul, Bhalla, Karan, Brucato, Antonio, Cross, David, Eisen, Alon , FREEDBERG, NAHUM A., Fuchs, Shmuel, Gaddam, Eliyazar, Gelfand, Eli V. , Grena, Paul, Halabi, Majdi , Harris, David C.H. , Karim, Amin, Kontzias, Apostolos , Kornberg, Robert, Latif, Faisal , Leibowitz, David , Lou, Pey Wen, Moriel, Mady , Roberts‐Thomson, Philip , Schiff, Elad , Siegel, Robert , Stokes, Michael B. , Sutej, Paul, Wittekind, Samuel G. , Witzling, Valentin, Cremer, Paul , Luis, Sushil Allen , Petersen, John W. , KWON, DEBBIE H., Brucato, Antonio, Insalaco, Antonella , Lewis, Basil S. , Nicholls, Stephen J. , Klein, Allan L. , Imazio, Massimo , Investigators, RHAPSODY, Atar, Shaul , Brucato, Antonio, Collins, Sean P. , Colquhoun, David Martin , Dwivedi, Girish , Gattorno, Marco , Karim, Amin, Knowlton, Kirk U. , Lotan, Dor , Portman, Michael A. , Schiff, Elad, Siegel, Robert, Zukermann, Robert

Mayo Clinic

European Heart Journal - Imaging Methods and Practice | May 26, 2023 | Volume: 1 | Issue: 1 | Pages: No page available

10.1093/ehjimp/qyad003 | PMID 39044797 Get It

Abstract Aims In this protocol-predefined substudy of the RHAPSODY trial, the primary aim was to assess whether pericardial late gadolinium enhancement (LGE) was associated with time to pericarditis recurrence. Methods and results RHAPSODY was a Phase 3 double-blind, placebo-controlled, randomized-withdrawal trial that demonstrated the efficacy of rilonacept in recurrent pericarditis (RP). Patients with a history of multiple RP and an active recurrence were enrolled and had the option to participate in a cardiac magnetic resonance (CMR) imaging substudy. CMRs were interpreted by a blinded independent core laboratory with prespecified criteria to define pericardial LGE. Compared to patients with trace or mild pericardial LGE (n = 9), patients with moderate or severe pericardial LGE (n = 16) generally had a higher number of recurrent episodes per year (5.3 vs. 3.9) and a higher mean CRP level (3.6 vs. 1.1 mg/dL). Overall, 10/14 (71.4%) who received a placebo had a recurrence compared to 0/11 (0%) who received rilonacept. In patients randomized to placebo who had moderate or severe pericardial LGE, the median time to recurrence was 4.2 weeks compared to 10.7 weeks in patients who had trace or mild pericardial LGE. At the conclusion of the event-driven randomized-withdrawal period, among patients receiving a placebo, 5/7 (71.4%) with trace or mild pericardial LGE and 5/7 (71.4%) with moderate or severe pericardial LGE had a recurrence. Conclusions Among patients with multiple RP, these preliminary findings support the concept of pericardial LGE as an imaging biomarker that may inform the duration of treatment and risk of recurrence with cessation of therapy and larger studies should be considered. ClinicalTrials.gov Identifier NCT03737110
Anesthetic Management and Deep Sedation After Emergence From General Anesthesia: A Retrospective Cohort Study
Deljou, Atousa , Soleimani, Jalal , Martin, David P. , Schroeder, Darrell R. , Schroeder, Darrell , Šprung, Juraj , Weingarten, Toby N.

Mayo Clinic

Anesthesia & Analgesia | April 3, 2023 | Volume: 136 | Issue: 6 | Pages: 1154-1163

10.1213/ane.0000000000006470 | PMID 37010956 Get It

BACKGROUND: Residual deep sedation during anesthesia recovery may predict postoperative complications. We examined the incidence and risk factors for deep sedation after general anesthesia. METHODS: We retrospectively reviewed health records of adults who underwent procedures with general anesthesia and were admitted to the postanesthesia care unit from May 2018 to December 2020. Patients were dichotomized by Richmond Agitation-Sedation Scale (RASS) score: ≤−4 (deeply sedated/unarousable) or ≥−3 (not deeply sedated). Anesthesia risk factors for deep sedation were assessed with multivariable logistic regression. RESULTS: Of the 56,275 patients included, 2003 had a RASS ≤−4 (35.6 [95% CI, 34.1–37.2] cases per 1000 anesthetics administered). On adjusted analyses, the likelihood of a RASS ≤−4 increased when more soluble halogenated anesthetics were used. Compared with desflurane without propofol, the odds ratio (OR [95% CI]) for a RASS ≤−4 was higher with sevoflurane (1.85 [1.45–2.37]) and isoflurane (4.21 [3.29–5.38]) without propofol. Compared with desflurane without propofol, the odds of a RASS ≤−4 further increased with use of desflurane-propofol (2.61 [1.99–3.42]), sevoflurane-propofol (4.20 [3.28–5.39]), isoflurane-propofol (6.39 [4.90–8.34]), and total intravenous anesthesia (2.98 [2.22–3.98]). A RASS ≤−4 was also more likely with the use of dexmedetomidine (2.47 [2.10–2.89]), gabapentinoids (2.17 [1.90–2.48]), and midazolam (1.34 [1.21–1.49]). Deeply sedated patients discharged to general care wards had higher odds of opioid-induced respiratory complications (2.59 [1.32–5.10]) and higher odds of naloxone administration (2.93 [1.42–6.03]). CONCLUSIONS: Likelihood of deep sedation after recovery increased with intraoperative use of halogenated agents with higher solubility and increased further when propofol was concomitantly used. Patients who experience deep sedation during anesthesia recovery have an increased risk of opioid-induced respiratory complications on general care wards. These findings may be useful for tailoring anesthetic management to reduce postoperative oversedation.
Interleukin‐1 Trap Rilonacept Improved Health‐Related Quality of Life and Sleep in Patients With Recurrent Pericarditis: Results From the Phase 3 Clinical Trial RHAPSODY
Brucato, Antonio , Lim-Watson, Michelle , Klein, Allan L. , Imazio, Massimo , Cella, David , Cremer, Paul , LeWinter, Martin M. , Lin, David , Lotan, Dor , Pancrazi, Massimo, Trotta, Lucia , Klooster, Brittany , Litcher‐Kelly, Leighann , Zou, Liangxing, Magestro, Matt , Wheeler, Alistair, Paolini, John F. , Abbate, Antonio , Abo‐Auda, Wael, Akhtar, Asif, Arad, Michael , Baibhav, Bipul, Bhalla, Karan, Cross, David, Eisen, Alon , FREEDBERG, NAHUM A., Fuchs, Shmuel, Gaddam, Eliyazar, Gelfand, Eli V. , Grena, Paul, Halabi, Majdi , Harris, David C.H. , Karim, Amin H., Kontzias, Apostolos , Kornberg, Robert, Latif, Faisal , Leibowitz, David , Lotan, Dor, Lim-Watson, Michelle Z , Klein, Allan , Luis, Sushil A , Lotan, Dor , Klooster, Brittany , Litcher-Kelly, Leighann , Paolini, John F , Brucato, Antonio , Cremer, Paul C , Imazio, Massimo , Luis, Sushil Allen , Atar, Shaul , Collins, Sean P. , Colquhoun, David Martin , Dwivedi, Girish , Gattorno, Marco , Insalaco, Antonella , Karim, Amin, Knowlton, Kirk U. , Lotan, Dor

Mayo Clinic

Journal of the American Heart Association | October 17, 2022 | Volume: 11 | Issue: 20 | Pages: No page available

10.1161/jaha.121.023252 | PMID 36250662 Get It

Background Recurrent pericarditis is characterized by painful flares and inflammation, which negatively impact health‐related quality of life. RHAPSODY (rilonacept inhibition of interleukin‐1 alpha and beta for recurrent pericarditis: a pivotal symptomatology and outcomes study) evaluated the efficacy and safety of rilonacept (IL‐1α and ‐β cytokine trap) in recurrent pericarditis. A secondary analysis of these data evaluated the patient‐reported outcome questionnaire score change during the trial. Methods and Results Participants completed 5 patient‐reported outcome (PRO) questionnaires assessing pericarditis pain, health‐related quality of life, general health status, sleep impact, and overall symptom severity. PRO score changes during the treatment run‐in period (12 weeks) and the blinded randomized withdrawal period (up to 24 weeks) were evaluated using descriptive statistics and mixed model repeated measures analyses. Participants with PRO data from the run‐in period (n=84) and the randomized withdrawal period (n=61; 30 rilonacept, 31 placebo) were included in analyses. Run‐in baseline PRO scores indicated that pericarditis symptoms during pericarditis recurrence impacted health‐related quality of life. All PRO scores significantly improved ( P <0.001) on rilonacept treatment during the run‐in period. For the randomized withdrawal period, PRO scores were maintained for participants receiving rilonacept. For those receiving placebo and who experienced a recurrence, PRO scores deteriorated at the time of recurrence and then improved following rilonacept bailout. At randomized withdrawal Week 24/End of Study, scores of participants who received bailout rilonacept were similar to those of participants who had continued rilonacept. Conclusions These results demonstrate the burden of pericarditis recurrences and the improved physical and emotional health of patients with recurrent pericarditis while on rilonacept treatment. These findings extend prior rilonacept efficacy results, demonstrating improvements in patient‐reported health‐related quality of life, sleep, pain, and global symptom severity while on treatment. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03737110.
American Board of Orthopaedic Surgery’s Initiatives Toward Competency-Based Education
Heest, Ann E. Van , Bednar, Michael S., Carpenter, James E. , Garvin, Kevin L. , Harrast, John J. , Martin, David , Murray, Peter M. , Peabody, Terrance D. , Saltzman, Charles L. , Saniei, Mona , Taitsman, Lisa A. , Marsh, J. Lawrence , Van Heest, Ann , Armstrong, April D , Carpenter, James E , Garvin, Kevin L , Harrast, John J , Martin, David F , Murray, Peter M , Peabody, Terrance D , Saniei, Mona , Taitsman, Lisa A , Marsh, J Lawrence

Mayo Clinic

JBJS Open Access | May 19, 2022 | Volume: 7 | Issue: 2 | Pages: No page available

10.2106/jbjs.oa.21.00150 | PMID 35620526 Get It

Abstract The American Board of Orthopaedic Surgery (ABOS) is the national organization charged with defining education standards for graduate medical education in orthopaedic surgery. The purpose of this article is to describe initiatives taken by the ABOS to develop assessments of competency of residents to document their progress toward the independent practice of orthopaedic surgery and provide feedback for improved performance during training. These initiatives are called the ABOS Knowledge, Skills, and Behavior Program. Web-based assessment tools have been developed and validated to measure competence. These assessments guide resident progress through residency education and better define the competency level by the end of training. The background and rationale for these initiatives and how they serve as steps toward competency-based education in orthopaedic residency education in the United States will be reviewed with a vision of a hybrid of time and competency-based orthopaedic residency education that will remain 5 years in length, with residents assessed using standardized tools.
Association of Indication for Hospitalization With Subsequent Amyloid Positron Emission Tomography and Magnetic Resonance Imaging Biomarkers
Šprung, Juraj , Laporta, Mariana L. , Petersen, Ronald C. , Mielke, Michelle M. , Jack, Clifford R. , Martin, David P. , Hanson, Andrew C. , Schroeder, Darrell R. , Schulte, Phillip J. , Przybelski, Scott A. , Morales, Diana J. Valencia , Vemuri, Prashanthi , Mielke, Michelle M , Valencia Morales, Diana J , Weingarten, Toby N , Vemuri, Prashanthi , Warner, David O , Jack, Clifford R , Sprung, J , Schroeder, Darrell , Knopman, David S. , Weingarten, Toby N. , Warner, David O.

Mayo Clinic

The Journals of Gerontology: Series A | March 12, 2022 | Volume: 78 | Issue: 2 | Pages: 304-313

10.1093/gerona/glac064 | PMID 35279026 Get It

AbstractBackgroundHospitalization in older age is associated with accelerated cognitive decline, typically preceded by neuropathologic changes. We assess the association between indication for hospitalization and brain neurodegeneration.MethodsIncluded were participants from the Mayo Clinic Study of Aging, a population-based longitudinal study, with ≥1 brain imaging available in those older than 60 years of age between 2004 and 2017. Primary analyses used linear mixed-effects models to assess association of hospitalization with changes in longitudinal trajectory of cortical thinning, amyloid accumulation, and white matter hyperintensities (WMH). Additional analyses were performed with imaging outcomes dichotomized (normal vs abnormal) using Cox proportional hazards regression.ResultsOf 2 480 participants, 1 966 had no hospitalization and 514 had ≥1 admission. Hospitalization was associated with accelerated cortical thinning (annual slope change −0.003 mm [95% confidence interval (CI) −0.005 to −0.001], p = .002), but not amyloid accumulation (0.003 [95% CI −0.001 to 0.006], p = .107), or WMH increase (0.011 cm3 [95% CI −0.001 to 0.023], p = .062). Interaction analyses assessing whether trajectory changes are dependent on admission type (medical vs surgical) found interactions for all outcomes. While surgical hospitalizations were not, medical hospitalizations were associated with accelerated cortical thinning (−0.004 mm [95% CI −0.008 to −0.001, p = .014); amyloid accumulation (0.010, [95% CI 0.002 to 0.017, p = .011), and WMH increase (0.035 cm3 [95% CI 0.012 to 0.058, p = .006). Hospitalization was not associated with developing abnormal cortical thinning (p = .407), amyloid accumulation (p = .596), or WMH/infarctions score (p = .565).ConclusionsMedical hospitalizations were associated with accelerated cortical thinning, amyloid accumulation, and WMH increases. These changes were modest and did not translate to increased risk for crossing the abnormality threshold.
Modest agreement between magnetic resonance and pathological tumor regression after neoadjuvant therapy for rectal cancer in the real world
Achilli, Pietro , Magistro, Carmelo , Calini, Giacomo , Bertoglio, Camillo Leonardo , Mari, Giulio , Maggioni, Dario, Tamburello, Sara , Coppola, Elisabetta , Spinelli, Antonino , Martín, David , Salvatori, Andrea , Simoni, Silvia De, Sheedy, Shannon P. , Grass, F , Achilli, P , Calini, G , Bertoglio, Camillo L , Spinelli, Antonino , Aziz, Mohamed A. Abd El , Ferrari, Giovanni , Peros, Georgios , Grass, Fabian , Hahnloser, Dieter , Fletcher, Joel G. , Larson, David W.

Mayo Clinic

International Journal of Cancer | February 22, 2022 | Volume: 151 | Issue: 1 | Pages: 120-127

10.1002/ijc.33975 | PMID 35191540 Get It

AbstractMagnetic resonance imaging (MRI) is routinely used for preoperative tumor staging and to assess response to therapy in rectal cancer patients. The aim of our study was to evaluate the accuracy of MRI based restaging after neoadjuvant chemoradiotherapy (CRT) in predicting pathologic response. This multicenter cohort study included adult patients with histologically confirmed locally advanced rectal adenocarcinoma treated with neoadjuvant CRT followed by curative intent elective surgery between January 2014 and December 2019 at four academic high‐volume institutions. Magnetic resonance tumor regression grade (mrTRG) and pathologic tumor regression grade (pTRG) were reviewed and compared for all the patients. The agreement between radiologist and pathologist was assessed with the weighted k test. Risk factors for poor agreement were investigated using logistic regression. A total of 309 patients were included. Modest agreement was found between mrTRG and pTRG when regression was classified according to standard five‐tier systems (k = 0.386). When only two categories were considered for each regression system, (pTRG 0‐3 vs pTRG 4; mrTRG 2‐5 vs mrTRG 1) an accuracy of 78% (95% confidence interval [CI] 0.73‐0.83) was found between radiologic and pathologic assessment with a k value of 0.185. The logistic regression model revealed that “T3 greater than 5 mm extent” was the only variable significantly impacting on disagreement (OR 0.33, 95% CI 0.15‐0.68, P = .0034). Modest agreement exists between mrTRG and pTRG. The chances of appropriate assessment of the regression grade after neoadjuvant CRT appear to be higher in case of a T3 tumor with at least 5 mm extension in the mesorectal fat at the pretreatment MRI.
Autoimmune conditions in the World Trade Center general responder cohort: A nested case‐control and standardized incidence ratio analysis
Sacks, Henry S. , Smirnoff, Margaret, Carson, Deborah A. , Cooney, Michael L. , Shapiro, Moshe , Hahn, Christopher J., Dasaro, Christopher R. , Crowson, Cynthia S. , Tassiulas, Ioannis, Hirten, Robert , Cohen, Benjamin L., Haber, Richard S., Crane, Michael A. , Harrison, Denise , Moline, Jacqueline , Udasin, Iris , Todd, Andrew C. , Teitelbaum, Susan L. , Crowson, Cynthia, Sloan, Nancy L , Davies, Terry F. , Simpson, David Martin , Luft, Benjamin J.

Mayo Clinic

American Journal of Industrial Medicine | November 26, 2021 | Volume: 65 | Issue: 2 | Pages: 117-131

10.1002/ajim.23313 | PMID 34825393 Get It

AbstractBackgroundThe World Trade Center (WTC) general responder cohort (GRC) was exposed to environmental toxins possibly associated with increased risk of developing autoimmune conditions.ObjectivesTwo study designs were used to assess incidence and risks of autoimmune conditions in the GRC.MethodsThree clinically trained professionals established the status of possible GRC cases of autoimmune disorders adhering to diagnostic criteria, supplemented, as needed, by specialists’ review of consenting responders’ medical records. Nested case‐control analyses using conditional logistic regression estimated the risk associated with high WTC exposure (being in the 9/11/2001 dust cloud or ≥median days' response worked) compared with low WTC exposure (all other GRC members'). Four controls were matched to each case on age at case diagnosis (±2 years), sex, race/ethnicity, and year of program enrollment. Sex‐specific and sensitivity analyses were performed. GRC age‐ and sex‐adjusted standardized incidence ratios (SIRs) were compared with the Rochester Epidemiology Project (REP). Complete REP inpatient and outpatient medical records were reviewed by specialists. Conditions meeting standardized criteria on ≥2 visits were classified as REP confirmed cases.ResultsSix hundred and twenty‐eight responders were diagnosed with autoimmune conditions between 2002 and 2017. In the nested case‐control analyses, high WTC exposure was not associated with autoimmune domains and conditions (rheumatologic domain odds ratio [OR] = 1.03, 95% confidence interval [CI] = 0.77, 1.37; rheumatoid arthritis OR = 1.12, 95% CI = 0.70, 1.77). GRC members had lower SIR than REP. Women's risks were generally greater than men's.ConclusionsThe study found no statistically significant increased risk of autoimmune conditions with WTC exposures.
Gait Speed and Instrumental Activities of Daily Living in Older Adults After Hospitalization: A Longitudinal Population-Based Study
Šprung, Juraj , Laporta, Mariana L. , Petersen, Ronald C. , Mielke, Michelle M. , Weingarten, Toby N. , Vassilaki, Maria , Martin, David P. , Schulte, Phillip J. , Hanson, Andrew C. , Schroeder, Darrell R. , Vemuri, Prashanthi , Laporta, Mariana, Mielke, Michelle M , Weingarten, Toby N , Vassilaki, Maria , Sprung, J , Vemuri, Prashanthi , Schroeder, Darrell , Knopman, David S. , Warner, David O.

Mayo Clinic

The Journals of Gerontology: Series A | March 2, 2021 | Volume: 76 | Issue: 10 | Pages: e272-e280

10.1093/gerona/glab064 | PMID 33650631 Get It

Abstract Background Hospitalization can impair physical and functional status of older adults, but it is unclear whether these deficits are transient or chronic. This study determined the association between hospitalization of older adults and changes in long-term longitudinal trajectories of 2 measures of physical and functional status: gait speed (GS) and instrumental activities of daily living measured with Functional Activities Questionnaire (FAQ). Method Linear mixed-effects models assessed the association between hospitalization (nonelective vs elective, and surgical vs medical) and outcomes of GS and FAQ score in participants (older than 60 years) enrolled in the Mayo Clinic Study of Aging who had longitudinal assessments. Results Of 4902 participants, 1879 had ≥1 hospital admission. Median GS at enrollment was 1.1 m/s. The slope of the annual decline in GS before hospitalization was −0.015 m/s. The parameter estimate (95% CI) for additional annual change in GS trajectory after hospitalization was −0.009 (−0.011 to −0.006) m/s, p &lt; .001. The accelerated GS decline was greater for medical versus surgical hospitalizations (−0.010 vs −0.003 m/s, p = .005), and nonelective versus elective hospitalizations (−0.011 vs −0.006 m/s, p = .067). The odds of a worsening FAQ score increased on average by 4% per year. Following hospitalization, odds of FAQ score worsening further increased (multiplicative annual increase in odds ratio per year [95% CI] following hospitalization was 1.05 [1.03, 1.07], p &lt; .001). Conclusions Hospitalization of older adults is associated with accelerated long-term decline in GS and functional limitations, especially after nonelective admissions and those for medical indications. However, for most well-functioning participants, these changes have little clinical significance.
Association of Hospitalization with Long‐Term Cognitive Trajectories in Older Adults
Šprung, Juraj , Petersen, Ronald C. , Vassilaki, Maria , Martin, David P. , Schulte, Phillip J. , Hanson, Andrew C. , Schroeder, Darrell R. , Laporta, Mariana L. , White, Robert J. , Vemuri, Prashanthi , Vassilaki, Maria , Sprung, J , Vemuri, Prashanthi , Schroeder, Darrell , Knopman, David S. , Mielke, Michelle M. , Weingarten, Toby N. , White, Robert J., Warner, David O.

Mayo Clinic

Journal of the American Geriatrics Society | October 31, 2020 | Volume: 69 | Issue: 3 | Pages: 660-668

10.1111/jgs.16909 | PMID 33128387 Get It

IMPORTANCE Hospitalizations are associated with cognitive decline in older adults. OBJECTIVE To determine the association between hospitalization characteristics and the trajectory of cognitive function in older adults. DESIGN Population‐based longitudinal study of cognitive aging. SETTING Olmsted Medical Center and Mayo Clinic, the only centers in Olmsted County, Minnesota, with hospitalization capacity. PARTICIPANTS Individuals without dementia at baseline, with consecutive cognitive assessments from 2004 through 2017, and at least one visit after the age of 60. MEASUREMENTS The primary outcome was longitudinal changes in global cognitive z ‐score. Secondary outcomes were changes in four cognitive domains: memory, attention/executive function, language, and visuospatial skills. Hospitalization characteristics analyzed included elective versus nonelective, medical versus surgical, critical care versus no critical care admission, and long versus short duration admissions. RESULTS Of 4,587 participants, 1,622 had 1 and more hospital admission. Before hospitalization, the average slope of the global z ‐score was −0.031 units/year. After hospitalization, the rate of annual global z ‐score accelerated by −0.051 (95% CI = −0.057, −0.045) units, P < .001, resulting in an estimated annual slope after the first hospitalization of −0.082. The accelerated decline was found in all four cognitive domains (memory, visuospatial, language, and executive, all P < .001). The acceleration of the decline in global z ‐score following hospitalization was greater for medical compared to surgical hospitalizations (slope change following hospitalization = −0.064 vs −0.034 for medical vs surgical, P < .001), and nonelective compared to elective admissions (slope change following hospitalization = −0.075 vs −0.037 for nonelective vs elective, P < .001). The acceleration of cognitive decline was not different for hospitalization with intensive care unit admission versus not. CONCLUSIONS Hospitalization of older adults is associated with accelerated decline of global and domain‐specific cognitive domains, with the rate of decline dependent upon type of admission. The clinical impact of this accelerated decline will depend on the individual's baseline cognitive reserve and expected longevity.
Leveraging the Capabilities of the FDA’s Sentinel System To Improve Kidney Care
Adimadhyam, Sruthi , Frazee, Erin N. , Cocoros, Noelle M. , Brown, Jeffrey S. , Maro, Judith C. , Corrigan‐Curay, Jacqueline , Martin, David , Nguyen, Michael , Platt, Richard , Li, Xiaojuan , Maro, Judith C , Li, Xiaojuan , Toh, Sengwee , Pan, Gerald J. Dal , Ball, Robert

Mayo Clinic

Journal of the American Society of Nephrology | October 19, 2020 | Volume: 31 | Issue: 11 | Pages: 2506-2516

10.1681/asn.2020040526 | PMID 33077615 Get It

The Sentinel System is a national electronic postmarketing resource established by the US Food and Drug Administration to support assessment of the safety and effectiveness of marketed medical products. It has built a large, multi-institutional, distributed data network that contains comprehensive electronic health data, covering about 700 million person-years of longitudinal observation time nationwide. With its sophisticated infrastructure and a large selection of flexible analytic tools, the Sentinel System permits rapid and secure analyses, while preserving patient privacy and health-system autonomy. The Sentinel System also offers enhanced capabilities, including accessing full-text medical records, supporting randomized clinical trials embedded in healthcare delivery systems, and facilitating effective collection of patient-reported data using mobile devices, among many other research programs. The nephrology research community can use the infrastructure, tools, and data that this national resource offers for evidence generation. This review summarizes the Sentinel System and its ability to rapidly generate high-quality, real-world evidence; discusses the program’s experience in, and potential for, addressing gaps in kidney care; and outlines avenues for conducting research, leveraging this national resource in collaboration with Sentinel investigators.